Object. The purpose of this study is to determine the efficacy of gamma knife radiosurgery (GKS) treatment of pituitary adenomas that have invaded the cavernous sinus.Methods. Sixteen patients were treated with GKS: three with nonfunctional adenomas and 13 with hormone-secreting (seven growth hormon...
Object. The purpose of this study is to determine the efficacy of gamma knife radiosurgery (GKS) treatment of pituitary adenomas that have invaded the cavernous sinus.Methods. Sixteen patients were treated with GKS: three with nonfunctional adenomas and 13 with hormone-secreting (seven growth hormone [GH] and six adrenocorticotropic hormone [ACTH]) adenomas. More than 16 Gy and 30 Gy were delivered to the tumor margin for nonfunctioning tumors and functioning tumors, respectively, keeping the dose to the optic pathways below 10 Gy. The median follow up was 3 years.Tumor growth control was achieved in all cases. In GH-producing tumors, four of six cases evaluated were endocrinologically normalized (serum GH < 10 mIU/L, somatomedin C < 450 ng/ml), and the remaining two cases also showed a steady decrease in the GH and somatomedin level. In ACTH-producing tumors, three of six cases were endocrinologically normalized (24-hour urinary-free cortisol < 90 mg/day), two were unchanged, and one showed hormonal recurrence 3 years after radiosurgery. Notably, there were no cases of permanent hypopituitarism or visual symptoms caused by radiosurgery.Conclusions. The authors data indicate that GKS can be a safe salvage therapy for invading pituitary adenomas, with effectiveness equivalent to conventional radiation therapy but with less risk of causing radiation-induced injury to the surrounding structures.
Object. The purpose of this study is to determine the efficacy of gamma knife radiosurgery (GKS) treatment of pituitary adenomas that have invaded the cavernous sinus.Methods. Sixteen patients were treated with GKS: three with nonfunctional adenomas and 13 with hormone-secreting (seven growth hormone [GH] and six adrenocorticotropic hormone [ACTH]) adenomas. More than 16 Gy and 30 Gy were delivered to the tumor margin for nonfunctioning tumors and functioning tumors, respectively, keeping the dose to the optic pathways below 10 Gy. The median follow up was 3 years.Tumor growth control was achieved in all cases. In GH-producing tumors, four of six cases evaluated were endocrinologically normalized (serum GH < 10 mIU/L, somatomedin C < 450 ng/ml), and the remaining two cases also showed a steady decrease in the GH and somatomedin level. In ACTH-producing tumors, three of six cases were endocrinologically normalized (24-hour urinary-free cortisol < 90 mg/day), two were unchanged, and one showed hormonal recurrence 3 years after radiosurgery. Notably, there were no cases of permanent hypopituitarism or visual symptoms caused by radiosurgery.Conclusions. The authors data indicate that GKS can be a safe salvage therapy for invading pituitary adenomas, with effectiveness equivalent to conventional radiation therapy but with less risk of causing radiation-induced injury to the surrounding structures.
참고문헌 (20)
Dolenc Transcranial epidural approach to pituitary tumors extending beyond the sella. Neurosurgery 41 542 1997
Fahlbusch Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir 92 93 1988 10.1007/BF01401978
Freda Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89 353 1998 10.3171/jns.1998.89.3.0353
Ganz The effects of gamma knife surgery of pituitary adenomas on tumor growth and endocrinopathies. Stereotact Funct Neurosurg (Suppl) 61 30 1993 10.1159/000100657
Hashimoto Transsphenoidal approach to infrasellar tumors involving the cavernous sinus. J Neurosurg 73 513 1990 10.3171/jns.1990.73.4.0513
Kliman Proton beam therapy of acromegaly: a 20-year experience Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy. 1984 1 191
Knosp Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 610 1993
Landolt Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 88 1002 1998 10.3171/jns.1998.88.6.1002
Leber Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 88 43 1998 10.3171/jns.1998.88.1.0043
Martinez Pituitary tumors and gamma knife surgery: clinical experience with more than two years of follow up. Stereotact Funct Neurosurg (Suppl) 70 110 1998 10.1159/000056413
McCord Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 39 437 1997 10.1016/S0360-3016(97)00335-0
Morange-Ramos Gamma-knife surgery for secreting pituitary adenomas. Acta Neurochir 140 437 1998 10.1007/s007010050121
Pollock Stereotactic radiosurgery for pituitary adenomas: imaging, visual, and endocrine results. Acta Neurochir (Suppl) 62 33 1994 10.1007/978-3-7091-9371-6_7
Tamiya Extradural temporopolar approach for giant pituitary adenomas invading the cavernous sinus and parasellar regions. No Shinkei Geka 26 803 1998
Thoren Stereotactic radiosurgery with the cobalt-60 gamma unit in the treatment of growth hormone-producing pituitary tumors. Neurosurgery 29 663 1991 10.1227/00006123-199111000-00004
Tsang Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys 30 557 1994 10.1016/0360-3016(92)90941-A
Tsang Role of radiation therapy in clinical hormonally active pituitary adenomas. Radiother Oncol 41 45 1996 10.1016/S0167-8140(96)91807-1
Watson Localization of pituitary adenomas by using intraoperative ultrasound in patients with Cushing's disease and no demonstrable pituitary tumor on magnetic resonance imaging. J Neurosurg 89 927 1998 10.3171/jns.1998.89.6.0927
Zierhut External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys 33 307 1995 10.1016/0360-3016(95)00071-6
※ AI-Helper는 부적절한 답변을 할 수 있습니다.